...
首页> 外文期刊>Journal of the American Academy of Child and Adolescent Psychiatry >Consensus report on impulsive aggression as a symptom across diagnostic categories in child psychiatry: implications for medication studies.
【24h】

Consensus report on impulsive aggression as a symptom across diagnostic categories in child psychiatry: implications for medication studies.

机译:关于儿童精神病学诊断类别中的症状-冲动攻击的共识报告:对药物研究的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To determine whether impulsive aggression (IA) is a meaningful clinical construct and to ascertain whether it is sufficiently similar across diagnostic categories, such that parallel studies across disorders might constitute appropriate evidence for pursuing indications. If so, how should IA be assessed, pharmacological studies designed, and ethical issues addressed? METHOD: Experts from key stakeholder communities, including academic clinicians, researchers, practicing clinicians, U.S. Food and Drug Administration, National Institute of Mental Health, industry sponsors, and patient and family advocates, met for a 2-day consensus conference on November 4 and 5, 2004. After evaluating summary presentations on current research evidence, participants were assigned to three workgroups, examined core issues, and generated consensus guidelines in their areas. Workgroup recommendations were discussed by the whole group to reach consensus, and then further iterated and condensed into this report postconference by the authors. RESULTS: Conference participants agreed that IA is a substantial public health and clinical concern, constitutes a key therapeutic target across multiple disorders, and can be measured with sufficient precision that pharmacological studies are warranted. Additional areas of consensus concerned types of measures, optimal study designs, and ethical imperatives. CONCLUSION: Derived from scientific evidence and clinical experience, these consensus-driven recommendations can guide the design of future studies.
机译:目的:确定冲动性攻击(IA)是否是有意义的临床构造,并确定其在各个诊断类别之间是否足够相似,从而使跨疾病的平行研究可能构成寻求适应症的适当证据。如果是这样,应如何评估IA,设计药理学研究和解决伦理问题?方法:来自主要利益相关者社区的专家,包括学术临床医生,研究人员,执业临床医生,美国食品与药物管理局,美国国家精神卫生研究所,行业赞助商以及患者和家庭拥护者,于11月4日举行了为期2天的共识会议。 2004年5月5日。在评估了有关当前研究证据的简要介绍后,参与者被分配到三个工作组中,研究了核心问题,并在各自领域内形成了共识性指南。整个小组讨论了工作组的建议,以达成共识,然后由作者在会议后进一步进行迭代和精简。结果:与会者同意IA是一个重大的公共卫生和临床问题,构成多种疾病的关键治疗靶标,并且可以以足够的精确度进行测量以确保需要进行药理学研究。共识的其他领域涉及测量类型,最佳研究设计和道德要求。结论:这些来自共识驱动的建议源自科学证据和临床经验,可以指导未来研究的设计。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号